Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy

Hórvath, Barbara; Demeter, Judit; Erős, Nóra; Hársing, Judit; Csomor, Judit; Matolcsy, András; Bottlik, Gyula; Gyõri, Gabriella; Marschalkó, Márta; Kárpáti, Sarolta

doi:10.1016/j.jaad.2008.12.045

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These combinations are beneficial to treat progressive and bulky disease and increase the response rates in comparison to individual drugs. However, they do not improve the overall survival of patients (Horváth et al, 2009;Barr et al, 2009;Tobinai et al, 2009). Moreover, the use of these cocktails should be carefully evaluated in high-risk patients, such as those with cardiovascular and respiratory diseases, especially the elderly (over 60 years of age) (Pontes et al, 2012).…”

Section: Results On the Clinical Efficacy Of Rituximabmentioning

confidence: 99%

Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma

Figueirêdo

Souza

Soares³

et al. 2014

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera ® ), which targets the CD20 protein, present in over 80% of NHL mature B cells. Recent clinical reports show a preference for combining the benefits of immunotherapy and adjuvant chemotherapy, thus generating safe and effective alternative treatments. The current review aimed at evaluating various aspects related to the use of rituximab for NHL, highlighting the possible inhibitory mechanisms of cell proliferation, the achieved clinical results, and the expected clinical and economic outcomes of treatments. The results from clinical tests indicate the need for a better understanding of the critical mechanisms of action of this antibody, which may maximize its therapeutic efficacy. This therapy not only represents a viable option to treat most types of NHLs, especially when associated with conventional chemotherapy, but also offers cost-utility and cost-effectiveness advantages.Uniterms: Non-Hodgkin's lymphoma. Antineoplastic combined chemotherapy/protocols. Adjuvant chemotherapy. Rituximab/application/Non-Hodgkin's lymphoma.O Linfoma não-Hodgkin (LNH) consiste em um grupo de neoplasias envolvendo, principalmente, as células B e representa 90% de todos os linfomas. A terapia atual disponível é baseada em quimioterapia associada ao anticorpo monoclonal rituximabe (Mab Thera ® ), que tem como alvo a proteína CD20, presente em mais de 80% das células B maduras do LNH. Recentes relatórios clínicos mostram preferência para combinar os benefícios da quimioterapia adjuvante e imunoterapia, gerando alternativas de tratamentos seguro e eficaz. O trabalho de revisão teve por objetivo avaliar vários aspectos relacionados à aplicação do rituximabe no LNH, destacando os possíveis mecanismos inibitórios da proliferação celular, os resultados clínicos obtidos e as implicações clínicas e econômicas esperadas para o tratamento. Os resultados de testes clínicos indicam a necessidade de uma melhor compreensão dos mecanismos críticos de ação deste anticorpo, que poderão maximizar a sua eficácia terapêutica. Essa terapia não representa apenas uma opção viável para o tratamento da maioria dos tipos de LNH, principalmente quando associado à quimioterapia convencional, mas, também, oferece vantagens em termos de custoutilidade e custo-efetividade.Unitermos: Linfoma não-Hodgkin. Quimioterapia combinada antineoplásica/protocolos. Quimioterapia adjuvante. Ribuximabe/aplicação/Linfoma não-Hodgkin.

show abstract

Section: Results On the Clinical Efficacy Of Rituximabmentioning

confidence: 99%

Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma

Figueirêdo

Souza

Soares³

et al. 2014

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…[13] Shimada reported that the addition of rituximab to CHOP or CHOP-like regimen revealed a better complete response rate, overall survival and 2-year progressionfree survival than those of chemotherapy alone in the patients with IVLBCL. [26] Despite the lack of standard therapy based on a large sample of clinical trials, the chemotherapy of R-CHOP with or without radiotherapy remains the currently recommended therapy for IVLBCL according to the available data [26,27] and NCCN practice guideline of DLBCL. The patient was diagnosed as primary prostate IVLBCL stage I according to the Ann Arbor staging criteria and was classified as the low-risk group based on the IPI score.…”

Section: Discussionmentioning

confidence: 99%

A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia

Zhu¹,

Xiao²,

Li³

et al. 2019

Medicine

View full text Add to dashboard Cite

Rational: Intravascular large B-cell lymphoma (IVLBCL) is a rare condition with a poor prognosis. The clinical presentation of primary lymphoma of the prostate is non-specific and it is difficult to distinguish from other prostatic diseases. The primary prostate IVLBCL is very rare, the diagnosis and treatment of which remains unclear. We reported a rare case to explore the diagnosis and treatment for the primary prostate IVLBCL.Patients concerns: This report described a case of a 71-year-old male diagnosed as primary prostate IVLBCL who presented with prostatic hyperplasia.Diagnosis: The patient first visited an outpatient clinic of urinary surgery because of urinary urgency and frequency and was diagnosed as benign prostatic hyperplasia in about January 2010. Four years later, the symptoms worsened quickly within two months. The diagnosis was still prostatic hyperplasia according to the physical examination and imaging. However, histopathology showed IVLBCL of prostate after transurethral resection of the prostate.Interventions: With the clear diagnosis of primary prostate stage I IVLBCL, the patient received immunochemotherapy of R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone) for 4 cycles and intensity-modulated radiation therapy (IMRT) including the region of prostate with the dose of 45Gy/25f.Outcomes: The response was complete remission after all treatment. The last follow-up time of the patient was June 20th, 2019, and no evidence of disease progression was observed. The progression-free survival of the patient was about 49 months until now.Lessons: The biopsy of prostate by prostatectomy plays an important role in the diagnosis and removal of the original lesion of primary prostate lymphoma. There is no consensus on therapeutic modalities for the treatment of primary prostate IVLBCL till now. Individual treatments include immunochemotherapy and/or radiotherapy according to the National Comprehensive Cancer Network (NCCN) practice guideline of diffuse large B cell lymphoma (DLBCL) based on the performance status and tumor staging of the patient. Timely and accurate diagnosis as well as the appropriate treatment may improve the clinical outcome.

show abstract

“…Historically, these patients have had a poor outcome but this perception may be distorted by the frequent diagnostic delay and attempts at treating patients with established organ failure. There are reports of successful outcome following treatment with R CHOP type regimens . Consider this diagnosis, with bone marrow biopsy, in any patient presenting with unexplained B symptoms, neurological compromise, skin rash and raised LDH.…”

mentioning

confidence: 99%